TabletsMRP Under Process
Official PMBI MRP is being updated for catalog code 2312.
Locate Jan Aushadhi KendraClinical Overview
Linagliptin (5 mg) is a xanthine-based dipeptidyl peptidase-4 (DPP-4) inhibitor on the WHO Model List of Essential Medicines. It binds tightly and pseudo-irreversibly to DPP-4 with 8-fold higher potency than other gliptins. Unlike other DPP-4 inhibitors, it is excreted predominantly unchanged via the enterohepatic bile system (95%) with less than 5% renal excretion. Consequently, it requires NO dose adjustments in patients with any degree of renal impairment or hepatic dysfunction, making it the DPP-4 inhibitor of choice in chronic kidney disease. Indicated for type 2 diabetes mellitus.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Take orally 5 mg once daily with a glass of water, with or without meals, at any time of day. No renal dose adjustment is ever needed, even in end-stage renal disease (ESRD) or dialysis.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Nasopharyngitis, cough, headache, diarrhea, hyperuricemia. Rare/Severe: Acute pancreatitis, severe arthralgia, and bullous pemphigoid.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Discontinue if pancreatitis is suspected. Safe and convenient for patients with renal impairment without dose titration. Strong CYP3A4 and P-gp inducers (rifampicin) reduce linagliptin efficacy.
Schedule H (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, clinical diagnosis, or treatment recommendations. Always consult a registered endocrinologist, diabetologist, or qualified physician before initiating, adjusting dosages of, or substituting any antidiabetic or hormonal medication.
Empagliflozin Tablets 10 mg
Empagliflozin (10 mg, 25 mg) is a highly selective SGLT2 inhibitor on the WHO Model List of Essential Medicines with landmark proven cardiovascular and renal mortality benefits. It selectively inhibits SGLT2 in the renal proximal convoluted tubules, promoting glycosuria and natriuresis, improving systemic hemodynamics, and reducing cardiac ventricular wall stress. Indicated for type 2 diabetes mellitus, reduction of cardiovascular death in adults with T2D and established CVD, heart failure (across the entire spectrum of LVEF), and chronic kidney disease.
Empagliflozin Tablets 25 mg
Empagliflozin (10 mg, 25 mg) is a highly selective SGLT2 inhibitor on the WHO Model List of Essential Medicines with landmark proven cardiovascular and renal mortality benefits. It selectively inhibits SGLT2 in the renal proximal convoluted tubules, promoting glycosuria and natriuresis, improving systemic hemodynamics, and reducing cardiac ventricular wall stress. Indicated for type 2 diabetes mellitus, reduction of cardiovascular death in adults with T2D and established CVD, heart failure (across the entire spectrum of LVEF), and chronic kidney disease.
Linagliptin 2.5mg + Metformin 1000mg Tablets
Metformin Hydrochloride is the foundational first-line biguanide oral antihyperglycemic agent on the WHO Model List of Essential Medicines. It activates AMP-activated protein kinase (AMPK) in the liver, suppressing mitochondrial respiratory chain complex I, thereby potently inhibiting hepatic gluconeogenesis and glycogenolysis, while stimulating peripheral glucose uptake into skeletal muscle and delaying intestinal glucose absorption. Does not stimulate beta-cell insulin secretion, having zero intrinsic hypoglycemia risk and promoting weight neutrality or mild weight loss. Indicated as the initial pharmacological drug of choice for type 2 diabetes mellitus in adults and children aged 10 and older, and off-label in polycystic ovary syndrome (PCOS).
Linagliptin 2.5mg + Metformin 500mg Tablets
Metformin Hydrochloride is the foundational first-line biguanide oral antihyperglycemic agent on the WHO Model List of Essential Medicines. It activates AMP-activated protein kinase (AMPK) in the liver, suppressing mitochondrial respiratory chain complex I, thereby potently inhibiting hepatic gluconeogenesis and glycogenolysis, while stimulating peripheral glucose uptake into skeletal muscle and delaying intestinal glucose absorption. Does not stimulate beta-cell insulin secretion, having zero intrinsic hypoglycemia risk and promoting weight neutrality or mild weight loss. Indicated as the initial pharmacological drug of choice for type 2 diabetes mellitus in adults and children aged 10 and older, and off-label in polycystic ovary syndrome (PCOS).